



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/565,462	01/20/2006	Stephen Mark McAllister	PU60404	9920
20462 7590 10/15/2010 GlaxoSmithKline GLOBAL PATENTS -US, UW2220 P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939				
EXAMINER				
TRAN, SUSAN T				
ART UNIT		PAPER NUMBER		
1615				
NOTIFICATION DATE		DELIVERY MODE		
10/15/2010		ELECTRONIC		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

US\_cipkop@gsk.com



## UNITED STATES DEPARTMENT OF COMMERCE

## U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10565462	1/20/06	MCALLISTER ET AL.	PU60404

GlaxoSmithKline  
GLOBAL PATENTS -US, UW2220  
P. O. BOX 1539  
KING OF PRUSSIA, PA 19406-0939

EXAMINER

S. TRAN

ART UNIT	PAPER
1615	20101012

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

The Reply filed 08/03/10 is considered noncompliant because it has failed to meet the requirement of 37 CFR 1.143, which requires that: the reply to the restriction requirement to be complete must include (i) an election of an invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Applicant's Reply filed 08/03/10 did not include an election of an invention. The Reply states that "as the restriction is flawed as to what is contained within the two groups, Applicant's cannot elect until the restriction is properly made". In response to Applicant's Remarks, however, the Examiner notes that the claims numbers disclosed in Group II was an obvious typographical error. For example, claim 71 is a dependent claim, which depends in claim 37 of Group I. The claims numbers for Groups I and II are as follow:

I. Claims 37-41 and 44-72 are drawn to a multi-component dosage form, classified in class 424, subclass 489.

II. Claims 73-106 are drawn to a capsule dosage form, classified in class 424, subclass 451.

Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

/S. TRAN/  
Primary Examiner, Art Unit 1615